Fibrodysplasia Ossificans Progressiva: Oral Ascorbate and Intravenous Bisphosphonate during Flare-Ups

REFERENCES

• Lutwak L: Myositis ossificans progressiva. Mineral, metabolic and radioactive calcium studies of the effects of hormones. Am J Med 37: 269–293, 1964.
   PubMed Web of Science ®Google Scholar
• Shore EM, Xu M, Feldman GJ, Fenstermocher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38(5): 525–527,2006.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Kohda M, Kanomata K, Nojima J, Nakamura A, Kamizono J, Noguchi Y, Iwakiri K, Kondo T, Kurose J, Endo K, Awakura T, Fukushi J, Nakashima Y, Chiyonobu T, Kawara A, Nishida Y, Wada I, Akita M, Komori T, Nakayama K, Nanba A, Maruki Y, Yoda T, Tomoda H, Yu PB, Shore EM, Kaplan FS, Miyazono K, Matsuoka M, Ikebuchi K, Ohtake A, Oda H, Jimi E, Owan I, Okazaki Y, Katagiri T: Constitutively activated ALK2 and increased smadl/5 cooperatively induce BMP signaling in fibrodysplasia ossificans progressiva. J Biol Chem 284(11): 7149–7156, 2009.
   PubMed Web of Science ®Google Scholar
• Shore EM, Feldman GJ, Xu M, Kaplan FS: The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3: 201–204, 2005.
   Google Scholar
• Nakajima M, Haga N, Takikawa K, Manabe N, Nishimura G, Ikegawa S: The ACVR1 617G>A mutation is also recurrent in three Japanese patients with fibrodysplasia ossificans progressiva. J Hum Genet 52(5): 473–475, 2007.
   PubMed Web of Science ®Google Scholar
• Connor JM, Smith R: The cervical spine in fibrodysplasia ossificans progressiva. Br J Radiol 55: 492–496, 1982.
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Shore EM, Glaser DL, Emerson S, the International Clinical Consortium on Fibrodysplasia Ossificans Progressiva: The medical management of fibrodysplasia ossificans progressiva: Current treatment considerations. Clin Proc Intl Clin Consort FOP 1(3): 1–71, 2005.
   Google Scholar
• Gannon FH, Kaplan FS, Olmsted E, Finkel G, Zasloff MA, Shore EM: Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Hum Pathol 28: 339–343, 1997.
   PubMed Web of Science ®Google Scholar
• Janoff HB, Muenke M, Johnson LO, Rosenberg A, Shore EM, Okereke E, Zasloff M, Kaplan FS: Fibrodysplasia ossificans progressiva in two half-sisters: Evidence for maternal mosaicism. Am J Med Genetics 61: 320–324, 1996.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Goa KL: Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47(6): 945–982, 1994.
   PubMed Web of Science ®Google Scholar
• HOFFMAN-LA: Ostac Product Monograph. Hoffmann-La Roche Ltd, Mississauga, ON, 1998.
   Google Scholar
• Fleisch HA, Russel RGG, Bisaz I, Muhlbauer RC: The inhibitory effect of phosphonates on the formation of calcium phosphonate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1: 12–18, 1970.
   PubMed Web of Science ®Google Scholar
• Alpigiani MG, Puleo MG, Di Bella E, Debbia C, Buzzanca C, Lester A: Dichloromethylenbiphosphonic acid in therapy of myositis ossificans progressiva (MOP). Minerva Pediatr 48: 159–163, 1996.
   PubMedGoogle Scholar
• Siden H: The boy who refused an IV: A case report of subcutaneous clodronate for bone pain in a child with Ewing sarcoma. J Med Case Rep 1: 7, 2007.
   PubMedGoogle Scholar
• Zasloff MA, Rocke DM, Crofford LJ, Hahn GV, Kaplan FS: Treatment of patients who have fibrodysplasia ossificans progressiva with isotretinoin. Clin Orthop 346: 121–129, 1998.
   Google Scholar
• Kaplan FS, Glaser DL, Shore EM: The thirteenth annual report of the fibrodysplasia ossificans progressiva (FOP) collaborative research project. FOP Connect 15(2): 1–32, 2004.
   Google Scholar
• Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, Groppe J, Shore EM: Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 22(1): 191–205, 2008.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JMC: Free radicals, other reactive species and disease. Free Radicals in Biology and Medicine, 3rd ed. Edited by B Halliwell, JMC Gutteridge. Clarendon Press, Oxford, 1999.
   Google Scholar
• Palhares DB, Leme ML: Myosite ossificans progressiva. J Pediatr 77(5): 431–434, 2001.
   Google Scholar
• Palhares DB: Myositis ossificans progressiva. Calcif Tissue Int 60: 394, 1997.
   PubMed Web of Science ®Google Scholar
• Anderson D, Phillips BJ, Yu T, Edwards AJ, Ayesh R, Butterworth KR: The effect of vitamin C supplementation on biomarkers of oxygen radical generated damage in human volunteers with low or high cholesterol levels. Environ Mol Mutagen 30: 161–174, 1997.
   PubMed Web of Science ®Google Scholar
• Candelario-Jalil E, Akundi RS, Bhatia HS, Lieb K, Appel K, Muñoz E, Hüll M, Fiebich BL: Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production. J Neuroimmunol 174(1–2): 39–51, 2006.
   PubMed Web of Science ®Google Scholar